Engineering of a mouse model of choline acetycholinesterase deficients using CRISPR/Cas9 gene editing
使用 CRISPR/Cas9 基因编辑构建胆碱乙酰胆碱酯酶缺陷小鼠模型
基本信息
- 批准号:10511979
- 负责人:
- 金额:$ 15.98万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-07-01 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:AblationAcetyl Coenzyme AAcetylcholineAddressAdultAffectAlbuterolAnimal ModelAnimalsApneaBiodistributionBiologicalBirthCRISPR/Cas technologyCanis familiarisCategoriesCessation of lifeCharacteristicsChildCholineCholine O-AcetyltransferaseCholinesterase InhibitorsCollectionCommunitiesConfocal MicroscopyCongenital Myasthenic SyndromesDataDependovirusDevelopmentDiagnosisDiseaseDisease modelDoseEngineeringEnzymesEphedrineEvaluationExperimental ModelsFamilyFeasibility StudiesFoundationsFutureGene MutationGenesGoalsHand StrengthHumanImmunohistochemistryImpairmentInjection of therapeutic agentInjectionsIntraperitoneal InjectionsInvestigational TherapiesKnock-inKnock-in MouseKnock-outKnockout MiceLifeLocationMeasuresMediatingMedicalMindModelingMotor NeuronsMouse StrainsMusMuscleMutant Strains MiceMutateMutationNeuraxisNeuronsNeurotransmittersOnline Mendelian Inheritance In ManPathogenesisPathogenicityPatientsPeripheralPersonsPharmaceutical PreparationsPharmacological TreatmentPhenotypePrevalenceProteinsRare DiseasesReportingResearchSingle-Gene DefectSpinalSympathomimeticsSynapsesTamoxifenTestingTherapeutic InterventionTimeToxic effectTransgenic MiceTransgenic OrganismsTranslatingTreatment EfficacyTropismVariantViral VectorWestern Blottingamifampridinebaseconditional knockoutefficacy evaluationgene therapygenetic pedigreegenome editinghuman diseasein vivoin vivo evaluationmotor deficitmouse modelneuronal cell bodypostnatalpostsynapticpresynapticpyridostigminerepositoryresponsestillbirththerapeutically effective
项目摘要
ENGINEERING OF A MOUSE MODEL OF CHOLINE ACETYLTRANSFERASE DEFICIENCY USING
CRISPR/CAS9 GENE EDITING
Scientific Abstract:
Choline acetyltransferase (ChAT) is the enzyme that resynthesizes the neurotransmitter acetylcholine, from
acetyl-CoA and choline at the soma of multiple types of neurons of the peripheral and central nervous system
(CNS). Mutations in the ChAT gene (CHAT) result in a potentially fatal form of human congenital myasthenic
syndrome (CMS) referred to as CMS associated with episodic apneas. Chat knockout (KO) mice are immobile
and die at birth, and conditional Chat KO (Chatflox/flox/Cre-ERT2) mice die a few weeks after the induction of Chat
ablation by an intraperitoneal injection of tamoxifen. However, the lethal Chatflox/flox/Cre-ERT2 phenotype can be
rescued in most cases by a single intracranial injection at the first day of life of 2x1013 vg/kg adeno-associated
virus type 9 (AAV9) carrying the human CHAT gene (AAV9-CHAT). Furthermore, injected mice can reach adult
life without developing obvious weakness. While these results are encouraging, the widespread depletion of
Chat induced in the conditional knock out model is not an adequate model of the human disease, nor the
injection of the therapeutic agent at the first day of life reflects the most likely time of therapeutic interventions
in humans. Thus, to refine the model of CMS due to ChAT deficiency, we plan to create knock in (KI) mice
homozygous for two previously identified human CHAT mutations, p.Val136 Met and p.Arg207His, using
CRISPR/Cas9 gene editing. We will then attempt to correct the phenotype of ChatKI/KI mice by injecting
intracisternally AAV9-CHAT during early postnatal life. The overall goal of the project is to generate an animal
model that will reproduce as faithfully as possible the human disease and to conduct a pilot feasibility study on
the efficacy of AAV9-CHAT mediated gene therapy in this newly developed animal model of CMS caused by
CHAT mutations.
胆碱乙酰转移酶缺乏症小鼠模型的建立
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RICARDO Anibal MASELLI其他文献
RICARDO Anibal MASELLI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RICARDO Anibal MASELLI', 18)}}的其他基金
Targeted ColQ gene therapy for Congenital Myasthenic Syndromes
先天性肌无力综合征的靶向 ColQ 基因治疗
- 批准号:
10602652 - 财政年份:2023
- 资助金额:
$ 15.98万 - 项目类别:
Congenital Myasthenic Syndromes: Pathogenic Mechanisms
先天性肌无力综合征:发病机制
- 批准号:
8610360 - 财政年份:2010
- 资助金额:
$ 15.98万 - 项目类别:
Congenital Myasthenic Syndromes: Pathogenic Mechanisms
先天性肌无力综合征:发病机制
- 批准号:
8220940 - 财政年份:2010
- 资助金额:
$ 15.98万 - 项目类别:
Congenital Myasthenic Syndromes: Pathogenic Mechanisms
先天性肌无力综合征:发病机制
- 批准号:
7891127 - 财政年份:2010
- 资助金额:
$ 15.98万 - 项目类别:
Congenital Myasthenic Syndromes: Pathogenic Mechanisms
先天性肌无力综合征:发病机制
- 批准号:
8017468 - 财政年份:2010
- 资助金额:
$ 15.98万 - 项目类别:
Congenital Myasthenic Syndromes: Pathogenic Mechanisms
先天性肌无力综合征:发病机制
- 批准号:
8420457 - 财政年份:2010
- 资助金额:
$ 15.98万 - 项目类别:
相似海外基金
The molecular basis for how acetyl-coenzyme A links metabolism to gene expression
乙酰辅酶 A 如何将代谢与基因表达联系起来的分子基础
- 批准号:
8783415 - 财政年份:2014
- 资助金额:
$ 15.98万 - 项目类别:
The molecular basis for how acetyl-coenzyme A links metabolism to gene expression
乙酰辅酶 A 如何将代谢与基因表达联系起来的分子基础
- 批准号:
8996048 - 财政年份:2014
- 资助金额:
$ 15.98万 - 项目类别:
The molecular basis for how acetyl-coenzyme A links metabolism to gene expression
乙酰辅酶 A 如何将代谢与基因表达联系起来的分子基础
- 批准号:
9125794 - 财政年份:2014
- 资助金额:
$ 15.98万 - 项目类别: